Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, REZLIDHIA (olutasidenib), GAVRETO (pralsetinib), R289, and Ocadusertib (Systemic) - Eli Lilly.
Last trade$42.56
Day change-$1.17 (-2.68%)
Day range$41.88 – $43.71
Volume122,895
Market cap$823M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$823.43M
Price / earnings
2.68×
Price / book
1.85×
Price / sales
2.86×
EV / sales
2.72×
EV / EBITDA
9.85×
Profitability
Earnings per share
$16.31
Return on assets
58.64%
Return on equity
69.02%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0.02×
Current ratio
2.39×
Quick ratio
2.19×
Cash ratio
0.59×
Cash flow
Price / cash flow
9.16×
Price / free cash flow
9.16×
Free cash flow
$89.91M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for RIGL, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$80.89M
$78.7M
$58.82M
$69.8M
$69.46M
$101.69M
$53.33M
$57.6M
Cost of revenue
$10.78M
$8.53M
$4.61M
$5.96M
$4.75M
$4.5M
$4.41M
$5.79M
Gross profit
$70.11M
$70.18M
$54.21M
$63.85M
$64.71M
$97.18M
$48.92M
$51.81M
Selling, general and administrative
$34.73M
$32.64M
$30.65M
$29.99M
$28.94M
$29.26M
$27.72M
$29.52M
Research and development
$18.27M
$13.96M
$11.68M
$10.69M
$7.35M
$6.82M
$8.44M
$5.63M
Total operating expenses
$53M
$46.6M
$42.33M
$40.68M
$36.29M
$36.08M
$36.15M
$35.15M
Operating income
$17.11M
$23.58M
$11.89M
$23.17M
$28.42M
$61.1M
$12.77M
$16.66M
Interest expense
-$257K
-$779K
-$1.43M
-$1.7M
-$1.89M
-$1.87M
-$1.85M
-$1.96M
Income before taxes
$17.41M
$23.59M
$11.66M
$22.71M
$27.62M
$59.98M
$11.51M
$15.22M
Income taxes
$4.22M
$6.3M
$3M
-$245.35M
-$280K
$369K
$65K
$881K
Net income
$13.19M
$17.29M
$8.65M
$268.07M
$27.9M
$59.61M
$11.45M
$14.34M
Net income attributable to common shareholders
$13.19M
$17.29M
$8.65M
$268.07M
$27.9M
$59.61M
$11.45M
$14.34M
EBITDA
$18.9M
$24.42M
$12.48M
$23.77M
$29.02M
$61.71M
$13.38M
$17.26M
Basic earnings per share
$0.70
$0.93
$0.47
$14.72
$1.55
$3.33
$0.64
$0.81
Diluted earnings per share
$0.65
$0.88
$0.44
$13.49
$1.46
$3.28
$0.63
$0.80
Recent news
Company coverage with links to the original publishers.
Arvinas, a clinical-stage biotech company specializing in protein degradation therapies, announced management participation in a fireside chat at the Jefferies Global Healthcare Conference on November 18, 2026. The company will present preliminary clinical data from early monotherapy dose escalation cohorts of ARV-393 (Zaloblideg), a PROTAC BCL6 degrader, at the 2026 American Society of Hematology Annual Meeting, including safety, pharmacokinetics, and pharmacodynamics data.
Rigel Pharmaceuticals (RIGL) reported quarterly earnings of $0.65 per share, missing the consensus estimate of $0.87 per share, representing a -25.29% earnings surprise. However, the company exceeded revenue expectations with $80.89 million versus the estimate of $78.27 million. The stock received a Zacks Rank #3 (Hold) rating, suggesting near-term performance in line with the market. Marker Therapeutics (MRKR) is expected to report a quarterly loss of $0.12 per share with revenues of $2.45 million.
United Therapeutics reported Q3 2026 earnings of $5.71 per share, missing the consensus estimate of $5.85, representing a -2.39% surprise. However, the company exceeded revenue expectations with $832.5 million versus the estimate of $783.3 million. The stock received a Zacks Rank #3 (Hold) rating, suggesting near-term performance in line with the market. The Medical - Drugs industry ranks in the top 41% of Zacks industries.
Arvinas received FDA approval for Veppanu (vepdegestrant) in May 2026, marking the first FDA-approved PROTAC protein degrader for treating ESR1-mutated breast cancer. The company out-licensed global rights to Rigel Pharmaceuticals for $70 million upfront plus up to $320 million in milestones and royalties. Arvinas' diversified pipeline includes candidates for lymphoma, Parkinson's disease, and solid tumors with data expected through 2027.
Arvinas announced the first patient dosing in a Phase 1/2 clinical trial of ARV-6723, an oral PROTAC designed to degrade HPK1 for advanced solid tumors. The drug is Arvinas' first immuno-oncology candidate and the first HPK1 PROTAC degrader to enter clinical trials in the US. Preclinical data showed potent HPK1 degradation, enhanced immune activity, and antitumor effects as monotherapy and in combination with anti-PD-1 therapy, including activity in anti-PD-1-resistant models.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.